Current development of the second generation of mTOR inhibitors as anticancer agents
- PMID: 22059905
- PMCID: PMC3249493
- DOI: 10.5732/cjc.011.10281
Current development of the second generation of mTOR inhibitors as anticancer agents
Abstract
The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, acts as a "master switch" for cellular anabolic and catabolic processes, regulating the rate of cell growth and proliferation. Dysregulation of the mTOR signaling pathway occurs frequently in a variety of human tumors, and thus, mTOR has emerged as an important target for the design of anticancer agents. mTOR is found in two distinct multiprotein complexes within cells, mTORC1 and mTORC2. These two complexes consist of unique mTOR-interacting proteins and are regulated by different mechanisms. Enormous advances have been made in the development of drugs known as mTOR inhibitors. Rapamycin, the first defined inhibitor of mTOR, showed effectiveness as an anticancer agent in various preclinical models. Rapamycin analogues (rapalogs) with better pharmacologic properties have been developed. However, the clinical success of rapalogs has been limited to a few types of cancer. The discovery that mTORC2 directly phosphorylates Akt, an important survival kinase, adds new insight into the role of mTORC2 in cancer. This novel finding prompted efforts to develop the second generation of mTOR inhibitors that are able to target both mTORC1 and mTORC2. Here, we review the recent advances in the mTOR field and focus specifically on the current development of the second generation of mTOR inhibitors as anticancer agents.
Figures


Similar articles
-
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.PLoS One. 2013 Nov 14;8(11):e80070. doi: 10.1371/journal.pone.0080070. eCollection 2013. PLoS One. 2013. PMID: 24244612 Free PMC article.
-
Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.Mol Cancer Ther. 2015 Apr;14(4):1014-23. doi: 10.1158/1535-7163.MCT-14-0669. Epub 2015 Feb 11. Mol Cancer Ther. 2015. PMID: 25673820 Free PMC article.
-
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.Cancer Chemother Pharmacol. 2013 May;71(5):1297-307. doi: 10.1007/s00280-013-2129-6. Epub 2013 Mar 12. Cancer Chemother Pharmacol. 2013. PMID: 23479136
-
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Paediatr Drugs. 2012. PMID: 22845486 Free PMC article. Review.
-
Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.Adv Biol Regul. 2017 May;64:39-48. doi: 10.1016/j.jbior.2016.12.001. Epub 2017 Jan 4. Adv Biol Regul. 2017. PMID: 28189457 Review.
Cited by
-
Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics.Pharmaceuticals (Basel). 2021 Mar 21;14(3):282. doi: 10.3390/ph14030282. Pharmaceuticals (Basel). 2021. PMID: 33801030 Free PMC article.
-
CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma.Cancer Sci. 2022 Jan;113(1):91-108. doi: 10.1111/cas.15188. Epub 2021 Nov 16. Cancer Sci. 2022. PMID: 34741373 Free PMC article.
-
The role of RICTOR amplification in targeted therapy and drug resistance.Mol Med. 2020 Feb 10;26(1):20. doi: 10.1186/s10020-020-0146-6. Mol Med. 2020. PMID: 32041519 Free PMC article. Review.
-
Crossregulation of rapamycin and elaiophylin biosynthesis by RapH in Streptomyces rapamycinicus.Appl Microbiol Biotechnol. 2022 Mar;106(5-6):2147-2159. doi: 10.1007/s00253-022-11847-9. Epub 2022 Feb 26. Appl Microbiol Biotechnol. 2022. PMID: 35218390
-
MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling.Oncotarget. 2017 Feb 21;8(8):12775-12783. doi: 10.18632/oncotarget.14299. Oncotarget. 2017. PMID: 28061443 Free PMC article.
References
-
- Kunz J, Henriquez R, Schneider U, et al. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993;73(3):585–596. - PubMed
-
- Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003;3(4):371–377. - PubMed
-
- Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell. 2003;12(2):271–280. - PubMed
-
- Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007;26(3–4):611–621. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous